Nordea Investment Management AB Sells 75,464 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Nordea Investment Management AB trimmed its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 95.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,378 shares of the biotechnology company’s stock after selling 75,464 shares during the quarter. Nordea Investment Management AB’s holdings in United Therapeutics were worth $1,210,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of UTHR. USA Financial Formulas bought a new position in United Therapeutics in the 3rd quarter worth $33,000. Brooklyn Investment Group bought a new position in United Therapeutics in the 3rd quarter worth $33,000. Capital Performance Advisors LLP bought a new position in United Therapeutics in the 3rd quarter worth $82,000. Values First Advisors Inc. bought a new position in United Therapeutics in the 3rd quarter worth $90,000. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in United Therapeutics by 14.0% in the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 42 shares during the period. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CFO James Edgemond sold 7,800 shares of United Therapeutics stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $350.00, for a total value of $2,730,000.00. Following the completion of the transaction, the chief financial officer now owns 6,978 shares in the company, valued at approximately $2,442,300. This trade represents a 52.78 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00. Following the transaction, the chief operating officer now owns 2,577 shares of the company’s stock, valued at $919,164.36. This trade represents a 79.51 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 134,630 shares of company stock worth $50,725,716. Corporate insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on UTHR shares. UBS Group raised their target price on United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. Argus raised their target price on United Therapeutics from $360.00 to $400.00 and gave the stock a “buy” rating in a report on Thursday, October 31st. Oppenheimer raised their price target on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, The Goldman Sachs Group raised their price target on United Therapeutics from $243.00 to $302.00 and gave the company a “neutral” rating in a report on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and thirteen have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $378.36.

United Therapeutics Stock Down 0.4 %

Shares of United Therapeutics stock opened at $364.97 on Monday. The firm has a market cap of $16.29 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 1.05 and a beta of 0.57. The business has a 50-day moving average price of $370.50 and a 200-day moving average price of $352.66. United Therapeutics Co. has a twelve month low of $208.62 and a twelve month high of $417.82.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. The firm had revenue of $748.90 million during the quarter, compared to analyst estimates of $722.62 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business’s quarterly revenue was up 22.9% compared to the same quarter last year. During the same quarter last year, the business posted $5.38 earnings per share. On average, equities analysts expect that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.